MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...

Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...

Millions of individuals rely on effective medications to manage diseases like cancer and diabetes. For those with chronic ...

In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.

In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to MaxCyte (MXCT – Research Report). The company’s shares ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell ...

At Texas A&M University, one research lab is changing the game of droplet microfluidics, a technique that involves conducting ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...